West Roxbury, MA, United States of America

Fan Yang

This inventor holds 22 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Meta-Optics Technology. Top assignees: Novartis Ag, Massachusetts Institute of Technology, 2Pi Inc.. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fan Yang. Retrieved from https://idiyas.com/inventor/fan-yang-gcl5tfi9

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 10)

% Patents Active = 81.8

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 8.3

ph-index = 7

Forward Citations = 127(Granted Patents)

Location History:

Burlington, MA (US) (2006 - 2013)
Roxbury, MA (US) (2013)
Cambridge, MA (US) (2012 - 2023)
West Roxbury, MA (US) (2013 - 2024)

Company Filing History:

Massachusetts Institute of Technology

Astex Therapeutics Limited

patents

5. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Meta-Optics

Nanofabrication

Ocular Applications

Metasurface Optics

Sensors

Cameras

Projectors

Inhibitors

Pyrrolopyrimidine

CDK4/6

SHP2

HCV NS5B

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12721520 - Meta-optics-based systems and methods for ocular applications (2026-09-01),

2. 12607456 - Wide field-of-view metasurface optics, sensors, cameras and projectors (2026-04-21),

3. 12429630 - Multifunctional metasurface flat optics (2025-09-30),

4. 12405400 - Methods and systems for metasurface-based nanofabrication (2025-09-02),

5. 12122761 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2024-10-22),

6. 11905283 - Compounds and compositions for inhibiting the activity of SHP2 (2024-02-20),

7. 11850001 - Meta-optics-based systems and methods for ocular applications (2023-12-26),

8. 11820778 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2023-11-21),

9. 11548865 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2023-01-10),

10. 11485742 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2022-11-01),

11. 11206978 - Meta-optics-based systems and methods for ocular applications (2021-12-28),

12. 10934285 - Compounds and compositions for inhibiting the activity of SHP2 (2021-03-02),

13. 9309252 - Pyrrolopyrimidine compounds as inhibitors of CDK4/6 (2016-04-12),

14. 8957074 - Pyrrolopyrimidine compounds as inhibitors of CDK4/6 (2015-02-17),

15. 8957068 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2015-02-17),

Title: Innovations and Contributions of Fan Yang in Pharmaceutical Science

Introduction: Fan Yang, a prominent inventor based in West Roxbury, MA, has made significant strides in the field of pharmaceutical science, holding an impressive portfolio of 18 patents. His innovative contributions focus on developing new compounds that can be utilized as therapeutic agents, particularly in areas such as receptor modulation and enzyme inhibition.

Latest Patents: Among his recent patents, Fan Yang has developed compounds known as 2-azaspiro[3.4]octane derivatives that function as M4 receptor agonists. These compounds are outlined in Formula (I) and include pharmaceutically acceptable salts. In addition to these derivatives, he has also introduced compounds aimed at inhibiting the activity of SHP2, described in a similar formula structure. These breakthroughs have the potential to offer new avenues for drug development targeting specific biological pathways.

Career Highlights: Fan Yang's career is marked by notable associations with leading research institutions and companies. He has made impactful contributions while working at Novartis AG and the Massachusetts Institute of Technology, where he engaged in cutting-edge research and collaborated with fellow innovators.

Collaborations: Fan Yang has collaborated with esteemed coworkers such as Zhuoliang Chen and Yaping Wang. These partnerships have likely enhanced the creative exchange of ideas, leading to further advancements in the pharmaceutical domain.

Conclusion: Fan Yang's work exemplifies the spirit of innovation in the pharmaceutical industry. With a significant number of patents to his name and a commitment to developing novel therapeutic agents, his contributions continue to influence advancements in healthcare. As he progresses, Fan Yang remains a key figure in the pursuit of innovative solutions for medical challenges.

Profile summary based on public USPTO records.